← board
SNGX
Soligenixdistress 7/10 · high distress / dilution risk$0.35-2%today-93% from 52w high
Immunology / Inflammation 1Oncology 1
Lead: cutaneous T-cell lymphoma · est. market ~$18B (approx, global)
Revenue
pre-revenue
Liquidity
$6M
Runway
0.6 yrs
Shares 1y
+246%
Price & events
-75.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.6%
1D
-1.6%
1W
-6.8%
1M
-74.2%
3M
-74.3%
6M
-75.1%
1Y
-93.1%
2Y
-99.8%
5Y
-99.9%
All
Overview
- Market Cap
- $5.25M
- Enterprise Value
- $-780.19K
- Volume
- 36.27K
- 52 Week Range
- $0.28 – $4.96
- Total Shares
- 14.82M
- Float Shares
- 14.72M
- Short %
- 2.76%
- % Held by Insiders
- 6.74%
- % Held by Institutions
- 5.33%
- RVOL
- 0.06x
- Beta
- 1.92
Pipeline stages · 2 programs
Hypericin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Dusquetide
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-07 | Phase 3 | Hypericin | CTCL/ Mycosis Fungoides, CTCL, Mycosis Fungoides, Cutaneous T Cell Lymphoma | 80 | recruiting |
| 2025-10-22 | Phase 2 | Hypericin, Placebo | Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris | 15 | completed |
| 2025-05-23 | Phase 2 | Dusquetideorphan | Behçet Disease | 8 | completed |
Catalyst news & presentations · 4
- second half of 2026Guided 55%readoutPhase 3HyBryte · Top-line results from confirmatory Phase 3 FLASH 2 trialSEC 8-K
- Q2 2026readoutPhase 3HyBryte · Interim analysis of confirmatory Phase 3 FLASH 2 trialSEC 8-K
- 2026-06-11trial discontinuedHyBryte (synthetic hypericin) · Company terminated HyBryte development programSEC 8-K
- 2024-08-16partnershipAt Market Issuance Sales Agreement with A.G.P./Alliance Global Partners for up to $5.8MSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2025-07-16Alliance Global PartnersBuy
Competitors — cutaneous T-cell lymphoma
Recent news
- 2026-07-21Soligenix (SNGX) seeks reverse stock split, higher share authorization to protect Nasdaq listing - Stock Titan
- 2026-06-26Soligenix (NASDAQ: SNGX) adds $2.5M to at-the-market stock program - Stock Titan
- 2026-06-26Soligenix ups ATM offering by $2.5M under Rodman & Renshaw agreement - TradingView
- 2026-06-26Soligenix (NASDAQ: SNGX) resets ATM capacity to $2.5M under S-3 - Stock Titan
- 2026-06-25SNGX Forecast — Price Target — Prediction for 2027 - TradingView
- 2026-06-25Enterprise value to revenue forward of Soligenix, Inc. – NASDAQ:SNGX - TradingView
- 2026-06-25Michael Liu, MJL Manager (SNGX) disclose 983,588 shares; related group holds material blocks - Stock Titan
- 2026-06-12Soligenix Received Notice of Noncompliance - TradingView
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.